CTI BioPharma Corp. (NASDAQ: CTIC) today announced the outcome of a Type B, End-of-Phase-2a meeting with the U.S. Food and ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

CTI BioPharma Announces Outcome From End-of-Phase-2a Meeting With U.S. Food and Drug Administration (FDA) Regarding Pacritinib for Treatment of MyelofibrosisJuly 18, 2019 7:00 AM